Method for detection and treatment of breast cancer

• US 6,342,483 B1
• Filed: 01/15/1998
• Issued: 01/29/2002
• Est. Priority Date: 01/14/1994
• Status: Expired due to Fees

• Current Assignee: Vanderbilt University
• Original Assignee: Vanderbilt University
• Inventors: Holt, Jeffrey T., Jensen, Roy A., Page, David L., Obermiller, Patrice S., Thompson, Marilyn E., Robinson-Benion, Cheryl L.
• Primary Examiner(s): Nguyen, Dave T.
• Assistant Examiner(s): Nguyen, Quang
• Application Number:
  US09/007,678
• Time in Patent Office: 1,475 Days
• Field of Search: 514/44, 435/320.1, 435/455-458, 435/375
• US Class Current: 514/44.00R
• CPC Class Codes: C07K 14/82 Translation products from oncogenes
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/112 Disease subtyping, staging or classification
• CPC Class Codes: C12Q 2600/136 Screening for pharmacological compounds
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: G01N 33/57415 of breast

Abstract

The present invention provides a method of detecting and diagnosing pre-invasive breast cancer by identifying differentially expressed genes in early, pre-invasive breast cancer tissue. Differentially expressed genes can be used as genetic markers to indicate the presence of pre-invasive cancerous tissues. Microscopically-directed tissue sampling techniques combined with differential display or differential screening of cDNA libraries are used to determine differential expression of genes in the early stages of breast cancer. Differential expression of genes in preinvasive breast cancer tissue is confirmed by RT-PCR, nuclease protection assays and in-situ hybridization of ductal carcinoma in situ tissue RNA and control tissue RNA. The present invention also provides a method of screening for compounds that induce expression of the BRCA1 gene, whose product negatively regulates cell growth in both normal and malignant mammary epithlial cells. The present invention also relates to gene therapy method using this gene.

Claims

1. A method for suppressing the growth of a sporadic epithelial breast tumor in a mammal, the method comprising infusing directly to said sporadic tumor a vector comprising a BRCA1 nucleic acid sequence encoding a BRCA1 protein having tumor suppressor activity, the nucleic acid sequence operatively linked to a promoter, wherein production of the BRCA1 protein results in a decrease in the growth rate of said epithelial breast tumor.

2. A method for reducing the growth of a sporadic epithelial breast tumor in a mammal, comprising:

infusing directly to said sporadic epithelial breast tumor a retroviral vector comprising BRCA1 DNA encoding a functionally active BRCA1 polypeptide operably linked to a promoter, wherein said BRCA1 polypeptide is expressed in said sporadic epithelial breast tumor at a level and for a period of time sufficient to reduce the growth of said sporadic epithelial breast tumor.

3. A method for reducing the growth of a sporadic epithelial breast tumor in a mammal, comprising:

infusing directly to said sporadic epithelial breast tumor a viral vector comprising BRCA1 DNA encoding a functionally active BRCA1 polypeptide operably linked to a promoter, wherein said BRCA1 polypeptide is expressed in said sporadic epithelial breast tumor at a level and for a period of time sufficient to reduce the growth of said sporadic epithelial breast tumor.

4. The method of claim 3, wherein the viral vector is an adenoviral vector.